Alvotech (ALVO) to Release Quarterly Earnings on Wednesday

Alvotech (NASDAQ:ALVO) is expected to issue its Q4 2025 results after the market closes on Wednesday, March 18th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $162.1950 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 19, 2026 at 8:00 AM ET.

Alvotech Trading Down 2.0%

ALVO opened at $3.47 on Monday. The firm’s 50 day simple moving average is $4.63 and its two-hundred day simple moving average is $5.99. The company has a market capitalization of $1.05 billion, a PE ratio of 15.09 and a beta of 0.16. Alvotech has a 1-year low of $3.45 and a 1-year high of $11.85.

Institutional Trading of Alvotech

A number of institutional investors and hedge funds have recently bought and sold shares of ALVO. Magnetar Financial LLC purchased a new stake in Alvotech in the 3rd quarter worth $86,000. Vanguard Group Inc. grew its position in shares of Alvotech by 2.7% during the third quarter. Vanguard Group Inc. now owns 4,348,151 shares of the company’s stock valued at $35,481,000 after purchasing an additional 114,255 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Alvotech by 0.7% during the second quarter. Geode Capital Management LLC now owns 230,291 shares of the company’s stock valued at $2,100,000 after purchasing an additional 1,574 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Alvotech by 1,707.7% in the fourth quarter. Millennium Management LLC now owns 357,176 shares of the company’s stock worth $1,832,000 after purchasing an additional 337,417 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC bought a new stake in shares of Alvotech in the second quarter worth about $1,782,000.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. UBS Group reduced their price objective on Alvotech from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Wall Street Zen downgraded Alvotech from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Barclays started coverage on Alvotech in a research report on Monday, December 8th. They issued an “underweight” rating and a $5.00 price target for the company. Morgan Stanley set a $10.00 price objective on Alvotech in a research note on Wednesday, December 3rd. Finally, Zacks Research cut Alvotech from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 18th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Alvotech currently has an average rating of “Reduce” and an average target price of $8.60.

Alvotech Company Profile

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).